Latest Orally disintegrating tablet Stories
WARREN, N.J., June 10 /PRNewswire/ -- MonoSol Rx, the developers of PharmFilm(R) technology and a drug delivery company specializing in dissolving thin film pharmaceutical products, announced today that the new drug application (NDA) for ondansetron orally dissolving film strip (ODFS) has been accepted for review by the U.S. Food and Drug Administration (FDA). Ondansetron ODFS was developed using MonoSol Rx's proprietary PharmFilm(R) technology to deliver the anti-emetic therapy ondansetron...
- Easy-to-swallow formulation provides important new alternative for patients RESEARCH TRIANGLE PARK, N.C., May 11 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved Lamictal(R) ODT(TM) (lamotrigine) Orally Disintegrating Tablets. Lamictal ODT uses a novel drug-delivery formulation to provide Lamictal in a tablet that has a pleasant taste and disintegrates on the tongue. One factor physicians should...
Files NDA for Ondansetron Orally Dissolving Film Strip BioAlliance to Resubmit Loramyc(R) NDA WOODCLIFF LAKE, N.J., April 9 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX), today provides an update on two of its pipeline products. Ondansetron Orally Dissolving Film Strip On April 7, 2009, Strativa submitted a New Drug Application (NDA) for its new orally dissolving...
Patent Addresses Use of Thin Film to Deliver Drugs and Vitamins via Pacifier or Porous Nipple WARREN, N.J., April 2 /PRNewswire/ -- MonoSol Rx, the developers of PharmFilm(R) technology and a drug delivery company specializing in dissolving thin film pharmaceutical products, today announced that it has been granted U.S. Patent No. 7,500,984 from the United States Patent and Trademark Office (USPTO). The patent relates to the delivery of an active ingredient, such as drugs and/or vitamins,...
DUBLIN, Ireland, January 9 /PRNewswire/ -- Azur Pharma Limited ("Azur Pharma") today announced that it licensed the exclusive U.S. marketing rights for Niravam(R) (alprazolam orally disintegrating tablets), Parcopa(R) (carbidopa-levodopa orally disintegrating tablets), Kemstro(TM) (baclofen orally disintegrating tablets) and Fluxid(TM) (famotidine orally disintegrating tablets) from UCB (Euronext: UCB). Financial terms were not disclosed. Niravam, Parcopa and Kemstro are central...
SOUTH BRUNSWICK, N.J., Nov. 12 /PRNewswire/ -- Tris Pharma, a privately owned, specialty pharmaceutical company, today unveiled a key component in the nation's fight against opioid abuse. Its new drug delivery platform, NoBuse(TM), offers a technology by which companies can deliver effective pain relief or ADHD products that are nearly impervious to abuse. In the United States, narcotic pain relievers have fueled a dangerous epidemic. One in five teens has abused a prescription pain...
Takeda Pharmaceutical Company, a research-based global pharmaceutical company, has submitted a new drug application to the Ministry of Health, Labour and Welfare for Actos orally disintegrating tablets 15 and 30, for treatment of type 2 diabetes. Takeda is the originator of the thiazolidinedione (TZD) class of oral anti-diabetic medications. Actos is a member of TZDs that help reduce insulin resistance, which is one of the major defects in type 2 diabetes. Because Actos orally...
Mylan Inc has announced that its subsidiary Mylan Pharmaceuticals Inc has received final approval from the FDA for its abbreviated new drug application for Carbidopa and Levodopa orally disintegrating tablets, 10mg/100mg, 25mg/100mg and 25mg/250mg. Carbidopa and Levodopa orally disintegrating tablets (ODT), indicated for the treatment of idiopathic Parkinson's disease, are the generic version of Schwarz Pharma's Parcopa ODT. This product, which Mylan has already started to ship, will be the...
PITTSBURGH, Sept. 22 /PRNewswire-FirstCall/ -- Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Carbidopa and Levodopa Orally Disintegrating Tablets (ODT), 10 mg/100 mg, 25 mg/100 mg and 25 mg/250 mg. Carbidopa and Levodopa ODT, indicated for the treatment of idiopathic Parkinson's disease, are the generic version of Schwarz Pharma's...
By Megan Rauscher NEW YORK (Reuters Health) - Orally disintegrating tablets, which dissolve on contact with saliva without the need for water, may help people with swallowing difficulties take their pills, researchers report. The team studied 36 adults with dysphagia, or problems with swallowing, while they downed conventional tablets or "RapiTab" quick-dissolving tablets, in a crossover fashion. While the subjects swallowed the pills, they underwent endoscopy looking at their throat...
